Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2441195 | 1.00 | KEAP1 (0.43) | KEAP1SMN1; SMN2HRH3GNAI3GNAO1 | |
| SCHEMBL2441151 | 1.00 | KEAP1 (0.43) | KEAP1SMN1; SMN2HRH3GNAI3GNAO1 | |
| SCHEMBL856513 | 0.94 | GNAI3 (0.40) | KEAP1SMN1; SMN2HRH3GNAI3GNAO1 | |
| SCHEMBL855029 | 0.94 | GNAI3 (0.40) | KEAP1SMN1; SMN2HRH3GNAI3GNAO1 | |
| SCHEMBL855030 | 0.94 | GNAI3 (0.40) | KEAP1SMN1; SMN2HRH3GNAI3GNAO1 | |
| SCHEMBL18233685 | 0.90 | KEAP1 (0.39) | KEAP1SMN1; SMN2HRH3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL18225621 | 0.88 | HRH3 (0.38) | KEAP1SMN1; SMN2HRH3GNAI3GNAO1 | |
| SCHEMBL2439975 | 0.86 | — | — | |
| SCHEMBL6333888 | 0.86 | — | — | |
| SCHEMBL4030838 | 0.86 | KEAP1 (0.58) | KEAP1SMN1; SMN2HRH3GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479858-B2 | Macrocyclic compounds as sting agonists and methods and uses thereof | LUPIN LIMITED (IN) | 2025-11-25 | — | — | US | disclosed |
| EP-4004002-B1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF | LUPIN LTD (IN) | 2024-07-10 | — | — | EP | disclosed |
| EP-4004002-B1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF | LUPIN LTD (IN) | 2024-07-10 | — | — | EP | disclosed |
| CN-114174303-B | Macrocyclic compounds as STING agonists and methods and uses thereof | 印度鲁宾有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20220289763-A1 | Macrocyclic Compounds as Sting Agonists and Methods and Uses Thereof | LUPIN LIMITED (IN) | 2022-09-15 | — | — | US | disclosed |
| EP-4004002-A1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF | Lupin Limited (IN) | 2022-06-01 | — | — | EP | disclosed |
| CN-114174303-A | Macrocyclic compounds as STING agonists, methods and uses thereof | 印度鲁宾有限公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2021014365-A1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF | LUPIN LIMITED (IN) | 2021-01-28 | — | — | WO | disclosed |
| WO-2021014365-A1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF | LUPIN LIMITED (IN) | 2021-01-28 | — | — | WO | disclosed |
| EP-2838895-B1 | AMINO-INDOLYL-SUBSTITUTED IMIDAZOLYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-9096579-B2 | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| EP-2838895-A1 | AMINO-INDOLYL-SUBSTITUTED IMIDAZOLYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2015-02-25 | — | — | EP | disclosed |
| US-20130281430-A1 | Amino-Indolyl-Substituted Imidazolyl-Pyrimidines and Their Use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| WO-2013156608-A1 | AMINO-INDOLYL-SUBSTITUTED IMIDAZOLYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479858-B2 | Macrocyclic compounds as sting agonists and methods and uses thereof | STING1, CGAS, MAVS | KEAP1 813/4885SMN1; SMN2 2159/4885HRH3 546/4885 |
| US-20130281430-A1 | Amino-Indolyl-Substituted Imidazolyl-Pyrimidines and Their Use as Medicaments | INMT, IDO1, CHRM1 | KEAP1 3635/4885SMN1; SMN2 1502/4885HRH3 38/4885 |
| US-20220289763-A1 | Macrocyclic Compounds as Sting Agonists and Methods and Uses Thereof | STING1, CGAS, MAVS | KEAP1 813/4885SMN1; SMN2 2159/4885HRH3 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.